Abstract
We describe an unusual interference in our routine high‐performance liquid chromatography (HPLC) assay of amiodarone and its active metabolite, desethylamiodarone, used to quantify the parent drug and the active metabolite in serum from the primary sample collection tube. The interfering peak had a retention time very similar to that of the authentic desethylamiodarone. Substitution of Corvac tubes with Vacutainer tubes for the collection and transportation of serum samples eliminated the source of interference. We routinely suggest the use of Vacutainer collection tubes for obtaining blood samples of cardiac patients undergoing amiodarone therapy. J. Clin. Lab. Anal. 11:232–234, 1997. © 1997 Wiley‐Liss, Inc.
Keywords: assay interference from primary collection tube; HPLC; amiodarone assay; desethylamiodarone, active metabolite
References
- 1. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lazzari JO, Elizari MW: Clinical efficacy of amiodarone as an antiar‐rhythmic agent. Am J Cardiol 38: 934–944, 1976. [DOI] [PubMed] [Google Scholar]
- 2. Kennedy RL, Griffiths H, Gray TA: Amiodarone and the thyroid. Clin Chem 35: 1882–1887, 1989. [PubMed] [Google Scholar]
- 3. Lam S: High performance liquid chromatography of amiodarone and desethylamiodarone in serum after microscale protein precipitation. J Chromatogr 381: 175–178, 1986. [DOI] [PubMed] [Google Scholar]